Sanara MedTech Inc. (SMTI)
NASDAQ: SMTI · Real-Time Price · USD
18.70
-0.23 (-1.22%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Company Description

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States.

The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.

It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement.

The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKŌS Antimicrobial Wound Gel, and BIAKŌS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body.

Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Sanara MedTech Inc.
Sanara MedTech logo
Country United States
Founded 1982
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 108
CEO Seth Yon

Contact Details

Address:
1200 Summit Avenue, Suite 414
Fort Worth, Texas 76102
United States
Phone 817 529 2300
Website sanaramedtech.com

Stock Details

Ticker Symbol SMTI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000714256
CUSIP Number 79957L100
ISIN Number US79957L1008
Employer ID 59-2220004
SIC Code 3842

Key Executives

Name Position
Suresh V. Muppalla President and Chief Executive Officer of THP
Seth D. Yon President, Chief Executive Officer and Director
Ronald T. Nixon Executive Chairman
Elizabeth B. Taylor Chief Financial Officer
Jacob A. Waldrop Chief Operating Officer
Ashley M. Mackey Principal Accounting Officer
Bill Fitzgerald Chief Compliance Officer
Tricia Matteson Vice President of Marketing
Tyler Palmer Chief Corporate Development and Strategy Officer
Nina Bionda Chief Research & Development Officer

Latest SEC Filings

Date Type Title
Apr 17, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 17, 2026 ARS Filing
Apr 17, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 17, 2026 DEF 14A Other definitive proxy statements
Apr 14, 2026 SCHEDULE 13G/A Filing
Mar 24, 2026 10-K Annual Report
Mar 24, 2026 8-K Current Report
Mar 2, 2026 8-K Current Report
Feb 6, 2026 SCHEDULE 13G Filing
Jan 23, 2026 8-K Current Report